2026 H1 -tulosraportti
UUTTA
Tänään
‧49 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 10.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 -tulosraportti 27.8. | ||
2025 H2 -tulosraportti 7.5. | ||
2026 Q1 -tulosraportti 30.4. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 10.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·15 t sittenKey points H1 2026: · Strong revenue growth, up 35.2 % compared to last year · Positive revenue outlook for the remainder of 2026 · Improved adjusted EBITDA year-to-date in 2026, NOK -12.1 million (NOK -13.6 million) · Clinical and preclinical data on HRO350 published in several peer-reviewed journals and at international conferences · Conducted several positive discussions with potential HRO350 partners, focus placed on next steps · New long-term financing of NOK 15 million established in H1 2026 In H1 2026, the sales performance for Arctic Bioscience's dietary supplement products was very positive. Strong order intake towards the end of 2025 and during Q1 2026 resulted in a good start to the year, and this trend continued throughout the rest of H1. Sales revenues for H1 2026 were 35.2 % higher than in the corresponding period in 2025. Revenue growth was achieved despite specific supplier-related delays towards the end of the reporting period, which resulted in some planned deliveries being postponed until July 2026. The postponed deliveries were completed at the beginning of Q3 and do not affect the company's assessment of underlying market demand or future prospects. «The development we have seen in the dietary supplement business in 2026 reflects the long-term and focused work we have carried out in recent years. We have established customer relationships that have been with us for a long time and continue to demand our products. At the same time, we have built new customer relationships in new markets through targeted efforts, and we are now seeing the results of this work. The sales outlook for the rest of 2026 is also positive», says CEO Christer L. Valderhaug. During 2026, Arctic Bioscience has continued its work on analyses from the HeROPA -study. Several publications on HRO350 have been released in internationally recognized, peer-reviewed scientific journals, and the HeROPA data has been presented at major scientific congresses, including the European Academy of Dermatology and Venereology Symposium in Athens. Further publications are under preparation. «We see that the results from the HeROPA study are well received in the scientific community, which supports our belief in the potential of HRO350. Going forward, we will publish further results from the study, continue the work on planning Phase III, and actively utilize feedback from potential partners to position the drug candidate for the next development phase», concludes Christer L. Valderhaug.
·1 päivä sittenOnly published on Liknedin, but this must surely be considered good news? The joy of science! Thrilled that new cellular data on immunomodulatory effects of herring roe oil in immune cells and skin cells has been published in a peer-reviewed journal. The study is related to our previous publication on SPMs in cells, and part of our quest to understand anti-inflammatory properties of our products. These cellular findings complement the clinical data in mild-to-moderate psoriasis. Grateful to our collaborators at Møreforsking and Nofima, and congratulations to the co-authors from our own science team. ORIGINAL RESEARCH article Front. Med., 24 August 2026 Sec. Dermatology Volume 13 - 2026 | https://doi.org/10.3389/fmed.2026.1684328 Herring roe oil exerts immunomodulatory effects on the IL-17/23 signaling axis in immune and skin cells as models for psoriasis
It doesn't look like the market is responding to what must be considered a good development in the company. It's probably news about a partnership most are waiting for, and in that way a solid foundation for the way forward.
·20.8.Biotech in vogue - and this company is extremely exciting...!We'll see. There are probably still " promising" discussions with potential partners. Something more than this standard phrase from the gang in Hovdebygda must come soon. Will confront them at the QA on 27.08- ·5.8.I smell opportunity here now…! Great news today:-) Potensiaje, as I have mentioned previously, is sky-high.
·10.7.I was wondering what others who have held a position for a long time (I have shares on a different platform than Nordnet) think about the development. I started buying before the rise to 16kr in -24, and bought more after the dip. My GAV is 7kr. I was wondering if someone could provide some motivation regarding the future value of this stock? The Nutra-part is doing well and they are showing promising data. Is it foolish to hope that this will rise back to old highs?I'm buying more at these levels. I think this goes under the radar for most people. A rock-solid company with rock-solid management - I think buying here will prove to be a bargain...!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 H1 -tulosraportti
UUTTA
Tänään
‧49 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·15 t sittenKey points H1 2026: · Strong revenue growth, up 35.2 % compared to last year · Positive revenue outlook for the remainder of 2026 · Improved adjusted EBITDA year-to-date in 2026, NOK -12.1 million (NOK -13.6 million) · Clinical and preclinical data on HRO350 published in several peer-reviewed journals and at international conferences · Conducted several positive discussions with potential HRO350 partners, focus placed on next steps · New long-term financing of NOK 15 million established in H1 2026 In H1 2026, the sales performance for Arctic Bioscience's dietary supplement products was very positive. Strong order intake towards the end of 2025 and during Q1 2026 resulted in a good start to the year, and this trend continued throughout the rest of H1. Sales revenues for H1 2026 were 35.2 % higher than in the corresponding period in 2025. Revenue growth was achieved despite specific supplier-related delays towards the end of the reporting period, which resulted in some planned deliveries being postponed until July 2026. The postponed deliveries were completed at the beginning of Q3 and do not affect the company's assessment of underlying market demand or future prospects. «The development we have seen in the dietary supplement business in 2026 reflects the long-term and focused work we have carried out in recent years. We have established customer relationships that have been with us for a long time and continue to demand our products. At the same time, we have built new customer relationships in new markets through targeted efforts, and we are now seeing the results of this work. The sales outlook for the rest of 2026 is also positive», says CEO Christer L. Valderhaug. During 2026, Arctic Bioscience has continued its work on analyses from the HeROPA -study. Several publications on HRO350 have been released in internationally recognized, peer-reviewed scientific journals, and the HeROPA data has been presented at major scientific congresses, including the European Academy of Dermatology and Venereology Symposium in Athens. Further publications are under preparation. «We see that the results from the HeROPA study are well received in the scientific community, which supports our belief in the potential of HRO350. Going forward, we will publish further results from the study, continue the work on planning Phase III, and actively utilize feedback from potential partners to position the drug candidate for the next development phase», concludes Christer L. Valderhaug.
- ·1 päivä sittenOnly published on Liknedin, but this must surely be considered good news? The joy of science! Thrilled that new cellular data on immunomodulatory effects of herring roe oil in immune cells and skin cells has been published in a peer-reviewed journal. The study is related to our previous publication on SPMs in cells, and part of our quest to understand anti-inflammatory properties of our products. These cellular findings complement the clinical data in mild-to-moderate psoriasis. Grateful to our collaborators at Møreforsking and Nofima, and congratulations to the co-authors from our own science team. ORIGINAL RESEARCH article Front. Med., 24 August 2026 Sec. Dermatology Volume 13 - 2026 | https://doi.org/10.3389/fmed.2026.1684328 Herring roe oil exerts immunomodulatory effects on the IL-17/23 signaling axis in immune and skin cells as models for psoriasisIt doesn't look like the market is responding to what must be considered a good development in the company. It's probably news about a partnership most are waiting for, and in that way a solid foundation for the way forward.
- ·20.8.Biotech in vogue - and this company is extremely exciting...!We'll see. There are probably still " promising" discussions with potential partners. Something more than this standard phrase from the gang in Hovdebygda must come soon. Will confront them at the QA on 27.08
- ·5.8.I smell opportunity here now…! Great news today:-) Potensiaje, as I have mentioned previously, is sky-high.
- ·10.7.I was wondering what others who have held a position for a long time (I have shares on a different platform than Nordnet) think about the development. I started buying before the rise to 16kr in -24, and bought more after the dip. My GAV is 7kr. I was wondering if someone could provide some motivation regarding the future value of this stock? The Nutra-part is doing well and they are showing promising data. Is it foolish to hope that this will rise back to old highs?I'm buying more at these levels. I think this goes under the radar for most people. A rock-solid company with rock-solid management - I think buying here will prove to be a bargain...!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 10.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 -tulosraportti 27.8. | ||
2025 H2 -tulosraportti 7.5. | ||
2026 Q1 -tulosraportti 30.4. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 10.11.2025 |
2026 H1 -tulosraportti
UUTTA
Tänään
‧49 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 10.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 -tulosraportti 27.8. | ||
2025 H2 -tulosraportti 7.5. | ||
2026 Q1 -tulosraportti 30.4. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 10.11.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·15 t sittenKey points H1 2026: · Strong revenue growth, up 35.2 % compared to last year · Positive revenue outlook for the remainder of 2026 · Improved adjusted EBITDA year-to-date in 2026, NOK -12.1 million (NOK -13.6 million) · Clinical and preclinical data on HRO350 published in several peer-reviewed journals and at international conferences · Conducted several positive discussions with potential HRO350 partners, focus placed on next steps · New long-term financing of NOK 15 million established in H1 2026 In H1 2026, the sales performance for Arctic Bioscience's dietary supplement products was very positive. Strong order intake towards the end of 2025 and during Q1 2026 resulted in a good start to the year, and this trend continued throughout the rest of H1. Sales revenues for H1 2026 were 35.2 % higher than in the corresponding period in 2025. Revenue growth was achieved despite specific supplier-related delays towards the end of the reporting period, which resulted in some planned deliveries being postponed until July 2026. The postponed deliveries were completed at the beginning of Q3 and do not affect the company's assessment of underlying market demand or future prospects. «The development we have seen in the dietary supplement business in 2026 reflects the long-term and focused work we have carried out in recent years. We have established customer relationships that have been with us for a long time and continue to demand our products. At the same time, we have built new customer relationships in new markets through targeted efforts, and we are now seeing the results of this work. The sales outlook for the rest of 2026 is also positive», says CEO Christer L. Valderhaug. During 2026, Arctic Bioscience has continued its work on analyses from the HeROPA -study. Several publications on HRO350 have been released in internationally recognized, peer-reviewed scientific journals, and the HeROPA data has been presented at major scientific congresses, including the European Academy of Dermatology and Venereology Symposium in Athens. Further publications are under preparation. «We see that the results from the HeROPA study are well received in the scientific community, which supports our belief in the potential of HRO350. Going forward, we will publish further results from the study, continue the work on planning Phase III, and actively utilize feedback from potential partners to position the drug candidate for the next development phase», concludes Christer L. Valderhaug.
- ·1 päivä sittenOnly published on Liknedin, but this must surely be considered good news? The joy of science! Thrilled that new cellular data on immunomodulatory effects of herring roe oil in immune cells and skin cells has been published in a peer-reviewed journal. The study is related to our previous publication on SPMs in cells, and part of our quest to understand anti-inflammatory properties of our products. These cellular findings complement the clinical data in mild-to-moderate psoriasis. Grateful to our collaborators at Møreforsking and Nofima, and congratulations to the co-authors from our own science team. ORIGINAL RESEARCH article Front. Med., 24 August 2026 Sec. Dermatology Volume 13 - 2026 | https://doi.org/10.3389/fmed.2026.1684328 Herring roe oil exerts immunomodulatory effects on the IL-17/23 signaling axis in immune and skin cells as models for psoriasisIt doesn't look like the market is responding to what must be considered a good development in the company. It's probably news about a partnership most are waiting for, and in that way a solid foundation for the way forward.
- ·20.8.Biotech in vogue - and this company is extremely exciting...!We'll see. There are probably still " promising" discussions with potential partners. Something more than this standard phrase from the gang in Hovdebygda must come soon. Will confront them at the QA on 27.08
- ·5.8.I smell opportunity here now…! Great news today:-) Potensiaje, as I have mentioned previously, is sky-high.
- ·10.7.I was wondering what others who have held a position for a long time (I have shares on a different platform than Nordnet) think about the development. I started buying before the rise to 16kr in -24, and bought more after the dip. My GAV is 7kr. I was wondering if someone could provide some motivation regarding the future value of this stock? The Nutra-part is doing well and they are showing promising data. Is it foolish to hope that this will rise back to old highs?I'm buying more at these levels. I think this goes under the radar for most people. A rock-solid company with rock-solid management - I think buying here will prove to be a bargain...!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt